Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
118 participants
OBSERVATIONAL
2021-04-01
2021-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Oxidative Stress in Polycystic Ovary Syndrome
NCT06826625
Molecular Basis of PCOS in Oocytes and Surrounding Cells
NCT04493788
The Results of the Mediterranean Diet for PCOS
NCT06442189
Polycystic Ovary Syndrome and BETATROPHIN
NCT04448730
Steroid Profiles in PCOS and Effect of OCP Treatment
NCT07161440
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phenotype A
Phenotype A was characterized by metabolic syndrome
Clusterin level
Clusterin plays a role in inflammation and oxidative stress processes such as metabolic syndrome, insulin resistance, and atherosclerosis
Phenotype B
phenotype B was characterized by the absence of metabolic syndrome
Clusterin level
Clusterin plays a role in inflammation and oxidative stress processes such as metabolic syndrome, insulin resistance, and atherosclerosis
Phenotype C
phenotype C was characterized by hyperandrogenism
Clusterin level
Clusterin plays a role in inflammation and oxidative stress processes such as metabolic syndrome, insulin resistance, and atherosclerosis
Phenotype D
phenotype D was characterized by the absence of hyperandrogenism
Clusterin level
Clusterin plays a role in inflammation and oxidative stress processes such as metabolic syndrome, insulin resistance, and atherosclerosis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Clusterin level
Clusterin plays a role in inflammation and oxidative stress processes such as metabolic syndrome, insulin resistance, and atherosclerosis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* natural bilateral ovaries and no functional cysts on transvaginal ultrasound.
Exclusion Criteria
* who have non-classical congenital adrenal hyperplasia (17 OHP value \>2 nmol/L)
* who have thyroid disease (TSH \>5 mlU/L),
* women with hyperprolactinemia (Prolactin\>30 mlU/mL)
* patients taking hormonal drugs or ovulation induction agents.
18 Years
45 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanliurfa Mehmet Akif Inan Education and Research Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nefise Nazlı YENIGUL
Ph.D. Assistant Professor Department of Obstetrics and Gynecology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nefise Nazlı Yenigül
Bursa, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-KAEK-25 2021/02-06
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.